Trial Profile
Retrospective Study of Patients With Type 2 Diabetes Mellitus on Dapagliflozin Therapy in Taiwan
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jan 2020
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 06 Dec 2019 Results assessing the glycemic control profile of dapagliflozin in Taiwanese T2DM patients under real world clinical setting, presented at the 2019 Congress of the International Diabetes Federation
- 21 Mar 2018 Status changed from recruiting to completed.
- 09 Jan 2018 Planned End Date changed from 30 Dec 2017 to 28 Feb 2018.